In this systematic review, we aim to evaluate whether COX-2 expression might act as a prognostic/predictive factor for overall survival after neoadjuvant radio(chemo)therapy in rectal cancer and whether COX-2 inhibitors might act as additional drugs except for standard therapy. The gene discussed is PTGS2; the disease is rectal cancer.